• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Lilly Disappoints All Around But Here's When I Would Invest

This stock is in a technical state of weakness and add that to the eroding fundamentals.
By STEPHEN GUILFOYLE
Aug 04, 2022 | 11:00 AM EDT
Stocks quotes in this article: LLY, BMY, PFE, MRK

On Thursday morning pharmaceutical giant Eli Lilly (LLY) released that firm's second quarter financial results. Investors would be disappointed.

The firm posted adjusted EPS of $1.25 (GAAP EPS: $1.05) on revenue of $6.488B. These top and bottom line results both fell short of Wall Street's expectations, with profitability significantly so. These numbers were "good" enough for earnings "growth" of -32% on sales "growth" of -4% (constant currency: -1%).

In Lilly's defense, both the adjusted and GAAP EPS numbers are inclusive of $0.46 worth of acquired IPR&D and development milestone charges. (The adjusted EPS print missed consensus by about $0.45.)

Revenue in the US increased 6% to $3.93B, primarily driven by a 14% increase in volume, partially offset by an 8% decrease in realized pricing. Revenue outside the US decreased 16% to $2.55B, driven by a 14% decrease in lower realized pricing and a 6% unfavorable exchange rate impact. These negative inputs were partially offset by a 5% increase in volume.

Reported gross margin increased 690 basis points to 78% of revenue largely driven by an excess inventory charge of $423M related to Covid antibodies that was recognized in Q2 2021 (the year ago comp). On an adjusted basis, gross margin increased 50 basis points to 79.8% of revenue. Adjusted operating income dropped 32% to $1.33B, while adjusted operating margin landed at 20.5%.

Selected Product Sales Performance

Trulicity (Type 2 Diabetes) sales increased 25% to $1.911.9B

Taltz (Autoimmune Diabetes) sales increased 7% to $606.2M.

Verzenio (Metastatic Breast Cancer) sales increased 72% to $588.5M.

Jardiance (Type 2 Diabetes, Cardiovascular Disease) sales increased 29% to $461M.

Humalog (Type 1, Type 2 Diabetes) sales decreased 26% to $447.1M.

Humulin (Type 1, Type 2, Gestational Diabetes) sales decreased 13% to $274M.

Alimta (Lung Cancer) sales decreased 63% to $227.7M.

Covid-19 antibodies sales decreased 13% to $129.1M.

Notable Announcement

Eli Lilly announced today that the FDA had accepted, with "Priority Review" designation, Donanemab for Alzheimer's Disease for review under the accelerated approval pathway. This is the big one, gang. If you are in LLY and okay with a forward looking earnings per share ratio of 37 times, this potential treatment for Alzheimer's is why.

Guidance

For the full year, Lilly reaffirmed its revenue outlook of $28.8B to $29.3B. This is unchanged from prior guidance. However, it is below the $29.1B that Wall Street was looking for. The firm sees adjusted gross margin of 78% which is unchanged from prior, and adjusted operating margin of 29%. That's down from 30%. The firm sees GAAP EPS of $6.96 to $7.11, which is down from prior guidance of $7.30 to $7.45. Lilly is also now projecting adjusted EPS of $7.90 to $8.05, which is down from prior guidance of $8.15 to $8.30.

Balance Sheet

There was no balance sheet information in the press release, which always annoys me. Why would any company make this information more difficult to find? When this happens, I go to the firm's website, where sometimes the information can be difficult to find, but is almost always available somewhere under the "investor" tab. Not today. While Eli Lilly has updated the Income Statement on their own website, to show information for the June quarter, they have not updated the site to show current balance sheet information nor current cash flow information.

So, I went back and took a look at the March quarter. Apparently, Eli Lilly has made a habit of releasing earnings one day and filing a Form 10-Q the following day with the Condensed Balance Sheet information and the Statement of Cash Flows that I seek. While I find this practice to be sloppy, that is neither here nor there. This is how Eli Lilly does it.

All I can tell you is that back in March, Eli Lilly ran with a net cash position that had been shrinking significantly from where it had been, ran with a current ratio of 1.26 which is acceptable, and a quick ratio of 0.98, which is close to "okay." Someone really has to ask these guys why they do not provide key information that investors and analysts should be looking for, on the same day that the firm releases earnings.

My Thoughts

The news on Donanemab (Alzheimer's) is encouraging. It did not make the selected product list above, but Mounjaro, which is a treatment for Type 2 Diabetes that was just approved this past May, has already accounted for sales of $16M versus expectations of $10M. This drug is also in clinical studies as an obesity treatment.

That's the positive.

The negatives are that the firm is lowering its own guidance for profitability, and acknowledges ongoing negative currency exchange rates. I also don't like that we have to wait until tomorrow (probably) to see an updated balance sheet. That really is not acceptable to me.

I had started writing this article considering perhaps a purchase on the dip, but can not pull such a trigger without seeing the financial guts of the operation. Besides, at seven times forward looking earnings, perhaps this is a trigger best not pulled. Bristol Myers-Squibb (BMY) , Pfizer (PFE) , and Merck (MRK) all trade at much cheaper valuations and pay shareholders much higher dividend yields.

Readers will see that LLY has been in an uptrend that goes back to the start of the year, and beyond. That said, the stock started selling off in late July and has not stopped. Relative Strength is very poor, the daily MACD has suffered a bearish crossover of the 26 day EMA by the two day EMA, and to top it all off... the stock has now given up its 50 day SMA.

This could very likely force portfolio managers to reduce exposure, just as the stock threatens the lower trend line of this regression model.

My plan, if I were thinking of investing in LLY would be to wait until the selling pauses. This stock is in a technical state of weakness. Add that to the eroding fundamentals, and for now... this name is hard pass for me.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Drug Approvals | Earnings | Investing | Stocks | Technical Analysis | Trading | Pharmaceuticals

More from Investing

Bearish Bets: 3 Stocks You Really Should Consider Shorting This Week

Bob Lang
Aug 7, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

I'm Banking on a Play in B. Riley Financial

Bret Jensen
Aug 7, 2022 7:30 AM EDT

Let me show you a covered-call setup in this investment management and financial services company.

The Secret to Dealing With Fear of Missing Out

James "Rev Shark" DePorre
Aug 6, 2022 10:00 AM EDT

FOMO is one of the most powerful forces in the stock market. Here's how to handle it.

3 Undervalued Blue Chip Dividend Stocks for High Long-Term Returns

Bob Ciura
Aug 6, 2022 7:00 AM EDT

This diversified group of high-yielders also happen to be undervalued.

So Far, Investors Are Willing to Reach Higher for the Market

James "Rev Shark" DePorre
Aug 5, 2022 4:24 PM EDT

After the miserable earlier part of the year, many investors are growing concerned that the market is going to run away to the upside without them.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login